Nirav Mehta — CEO Promise Tracker & Credibility Score

Promise Delivery Record

📊

Scorecard building

ConCallIQ tracks whether management promises made on earnings calls are delivered. Data for Nirav Mehta is being built as historical quarters are processed. Check back next quarter.

Notable Quotes

We expect to sustain 15% plus revenue growth organically and 25% revenue growth in acquired brand with 20% plus PAT growth in FY27.

Nirav Mehta · Corona Remedies Q4 FY26

Semaglutide brings a new dimension to the diabetic market as well as obesity market and generic semaglutide market has been exciting for sure.

Nirav Mehta · Corona Remedies Q4 FY26

Earnings Appearances

Corona Remedies · Q4 FY26

Read earnings analysis →